Myriad Genetics
MYGN
270 hedge funds and large institutions have $2.38B invested in Myriad Genetics in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 109 increasing their positions, 90 reducing their positions, and 48 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 90
1% more funds holding
Funds holding: 267 → 270 (+3)
6% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 48
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $2.62B → $2.38B (-$245M)
74% less call options, than puts
Call options by funds: $43.4M | Put options by funds: $168M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCG
Luxor Capital Group
New York
|
+$73.2M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
+$55.6M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$47.8M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$38.8M |
| 5 |
SCM
Snow Capital Management
Sewickley,
Pennsylvania
|
+$38.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
-$173M |
| 2 |
Renaissance Technologies
New York
|
-$54.9M |
| 3 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$54.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$26.2M |
| 5 |
Goldman Sachs
New York
|
-$26.1M |
MYGN Hedge Fund Activity: Q4 2013 in Review
270 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2013, worth a combined $2.38B — down 9.4% from $2.62B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new MYGN positions and 48 closed out — a net gain of 3 holders — while 109 added to existing stakes and 90 trimmed.
The largest buyer was Luxor Capital Group, adding an estimated $73.2M. The largest seller was Manning & Napier Advisors, exiting entirely with an estimated $173M sold.
- 270 institutional investors held Myriad Genetics (MYGN) as of Q4 2013, up from 267 in Q3 2013.
- Funds reported $2.38B of Myriad Genetics stock for Q4 2013, down 9.4% quarter-over-quarter.
- 51 funds opened new Myriad Genetics positions in Q4 2013 and 48 closed out, a net change of +3 holders.
- The largest Myriad Genetics buyer in Q4 2013 was Luxor Capital Group, an estimated $73.2M added.
- The largest Myriad Genetics seller in Q4 2013 was Manning & Napier Advisors, an estimated $173M sold.
Based on aggregated 13F filings for Q4 2013.